What Home Sleep Apnea Tests Actually Measure
A home sleep apnea test (HSAT) is an FDA-cleared Type III or Type IV ambulatory device that records a subset of the physiological signals captured in a full polysomnography lab study. Most devices record airflow (via a nasal cannula or thermistor), respiratory effort (via chest and abdominal belts), blood oxygen saturation (SpO2 via pulse oximetry), and heart rate. Higher-end devices such as the WatchPAT also add peripheral arterial tone and actigraphy to better differentiate true sleep from wakefulness.
The primary output is the Apnea-Hypopnea Index (AHI) — the number of complete or partial airway obstructions per hour of estimated sleep. Most devices also report the Oxygen Desaturation Index (ODI), which counts the number of times SpO2 drops 3–4 percent below baseline per hour. An ODI that closely mirrors the AHI strengthens diagnostic confidence. According to the American Academy of Sleep Medicine, HSATs are validated for detecting moderate-to-severe obstructive sleep apnea in adults with a high pre-test probability and no significant comorbidities.
Who Qualifies for a Home Test vs an In-Lab Sleep Study
Home sleep tests are appropriate for adults who have a high clinical suspicion of uncomplicated obstructive sleep apnea — meaning they snore regularly, have witnessed apneas or gasping episodes reported by a partner, and experience excessive daytime sleepiness. Most insurance plans will cover an HSAT as a first-line diagnostic tool in these cases.
In-lab polysomnography (PSG) is recommended instead when the patient has significant heart failure, chronic obstructive pulmonary disease, obesity hypoventilation syndrome, suspected central sleep apnea, or restless legs syndrome. Children should always be evaluated in a lab. If your initial home test is negative but symptoms persist strongly, an in-lab study is the appropriate next step, because home devices can miss positional or REM-specific apnea events that a full PSG would capture across all sleep stages.
How to Interpret Your AHI From a Home Device
The AASM defines severity thresholds as follows: AHI of 5–14.9 events per hour is mild OSA; 15–29.9 is moderate; and 30 or above is severe. However, it is important to understand that home devices calculate AHI based on total recording time, not verified sleep time. Because you are awake for some portion of the recording, your true AHI may be underestimated by 10–20 percent compared to lab measurement.
Pay particular attention to your minimum SpO2 reading alongside the AHI. An AHI of 12 with a minimum SpO2 of 78 percent indicates more severe oxygen disruption than an AHI of 18 with a minimum SpO2 of 88 percent. Your physician will use the full report — including the hypnogram showing event timing, the oxygen trend graph, and positional data — to make treatment decisions rather than relying on the AHI number alone.
Accuracy Limitations Compared to Polysomnography
Multiple validation studies show that home sleep tests have a sensitivity of roughly 79–85 percent and a specificity of 77–90 percent for detecting moderate-to-severe OSA when compared against PSG. This means approximately 1 in 6 patients with true moderate OSA will receive a falsely negative home result. Several factors reduce accuracy: lead displacement during sleep, mouth breathing bypassing the nasal cannula, central apneas being misclassified, and devices that rely on auto-scoring algorithms without technician review.
The absence of EEG in home devices is the most fundamental limitation. Without measuring brain waves, home tests cannot confirm sleep staging, cannot identify frequent cortical arousals caused by upper airway resistance syndrome (UARS), and cannot detect periodic limb movements. If your home test is borderline (AHI 4–9) but your daytime symptoms are significant, discuss with your physician whether a split-night or full diagnostic PSG would provide more clinically actionable data.
Next Steps After a Positive Home Sleep Apnea Result
A positive home test result opens three primary treatment pathways depending on severity. For mild OSA (AHI 5–14.9), oral appliance therapy using a mandibular advancement device is a first-line treatment endorsed by both the AASM and the American Academy of Dental Sleep Medicine. Devices that simultaneously advance the jaw and stabilize the tongue — such as the Snorple mouthpiece — are particularly effective because they address both anatomical contributors to airway collapse.
For moderate-to-severe OSA (AHI 15+), CPAP remains the gold standard, but compliance rates are historically low. Your physician may recommend a titration study to determine optimal CPAP pressure, or may offer auto-titrating CPAP (APAP) as an alternative. Positional therapy is an adjunct that can meaningfully reduce AHI in patients whose events cluster in the supine position. Whatever treatment path you pursue, a follow-up home test or oximetry study 6–8 weeks after starting therapy is standard practice to verify that your AHI has been adequately controlled.
Take Action Tonight
If snoring affects you or someone you love, the solution does not have to be complicated or expensive. The Snorple mouthpiece uses dual MAD and TSD technology to keep your airway open naturally while you sleep.